Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Discovery & Development Dosage Forms, COVID-19, Drug Discovery

Gilead Goes Ferreting

A study carried out on ferrets at Georgia State University’s Center for Translational Antiviral Research, funded by Gilead Sciences and the National Institutes of Health, has tested the potential of a new oral variant of Gilead’s remdesivir, the only as-yet approved antiviral treatment for COVID-19. The approved form of remdesivir is currently available only via intravenous delivery.

In glad news for the participating mustelids, the study found that the drug was effective. If approved, the oral variant would improve access to remdesivir and allow patients to begin receiving doses outside of hospital – an option intravenous remdesivir does not offer. The rapid chemical conversion conferred by the pill delivers the same bioactive to patients, faster. In a statement, first author Robert Cox said, “Orally available antivirals will provide health care workers with a powerful weapon to combat the highly infectious SARS-CoV-2 variants that are active in the community now.”

The ferrets were not available for comment.

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Angus Stewart

Angus is Associate Editor of The Medicine Maker

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine